Drugs Made In America Acquisition II Corp
DMIIBuild a strategy around DMII
Drugs Made In America Acquisition II Corp AI Insights
Informational only. Not investment advice.Snapshot
- Pre-revenue SPAC with 502M raised via IPO, trading at 0.61x book value (294M market cap vs 483M equity) - 39% discount to NAV[P/B Ratio]
- Cash of 315K vs 501M trust assets implies 500M+ held in trust pending deal - minimal operating liquidity[Cash and Equivalents]
- Zero debt with 219K working capital and 156K annual G&A burn - ~18 months runway at current rate[Working Capital]
Watch Triggers
- Total Revenue: Any revenue recognition — Signals business combination completed - fundamentally different investment
- Cash and Equivalents: Increase above 1M or trust redemption activity — Trust movement indicates deal progress or liquidation timeline
- Volume: Sustained increase above 100K daily — May signal deal announcement leak or institutional interest
Bull Case
39% discount to NAV (0.61x P/B) provides downside protection - liquidation would return ~1.64x current price assuming full trust value
502M war chest targeting US pharma manufacturing aligns with reshoring trend and CHIPS-style drug security legislation
Bear Case
Zero operating history, no identified target, and 11.7K daily volume creates severe illiquidity risk - may not exit at NAV
SPAC sponsor dilution typically 20%+ on deal completion - current NAV discount may not survive merger economics
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage DMII's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
SPAC will either complete pharma acquisition or liquidate at ~NAV within 12-24 months
- 502M trust capital seeking US drug manufacturing target
- Typical SPAC deadline forces action within 24 months
- Healthcare/pharma focus per company name
Valuation Context
Caveats
DMII Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$640.82M | — | ||
$640.92M | — | ||
75 | — | ||
$0 | — | ||
$0.13 | — | ||
0% | — | ||
0% | — | ||
$-1.11M | — | ||
3.49% | — | ||
Beta 5Y (Monthly) | unknown | — |
DMII Dividend History
DMII Stock Splits
DMII SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/14/26 | 03/31/26 | 10-Q | |
04/15/26 | 12/31/25 | Unknown | |
11/18/25 | 09/30/25 | 10-Q | |
09/25/25 | 06/30/25 | 424B4 | |
07/21/25 | 03/31/25 | S-1 |